Femoral Block With or Without Ropivacaine for Analgesia After Total Knee Replacement (TKR) (TKR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00910013|
Recruitment Status : Completed
First Posted : May 29, 2009
Last Update Posted : February 28, 2011
Total knee replacement is a painful procedure. Many solutions have been proposed to diminish the post-operative doses of narcotics, including nerve blocks.
The purpose of the study is to compare if the adjunction of intra-articular ropivacaine to a femoral block is more effective on narcotics consumption than the block alone after TKR.
|Condition or disease||Intervention/treatment||Phase|
|Total Knee Replacement||Drug: Ropivacaine||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized Trial Comparing the Efficacy on Post-operative Analgesia of Intra-articular Ropivacaine Added to a Femoral Block After Total Knee Replacement|
|Study Start Date :||April 2006|
|Primary Completion Date :||March 2008|
|Study Completion Date :||March 2008|
Experimental: Ropivacaine + femoral block
After the surgery is proceeded and after the closure of the joint capsule, 20 cc of ropivacaine 0.5% is inserted intra-articular through a catheter.
0.5% intra-articular ropivacaïne (20cc)
- Narcotic consumption per 24 hours after surgery (mg/kg) [ Time Frame: 48 hours ]
- VAS score at 24 hours [ Time Frame: 48 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00910013
|Québec, Quebec, Canada, G1J1Z4|
|Principal Investigator:||Dr Stéphane Pelet, MD,PhD||Hôpital Enfant-Jésus|